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Background: Alopecia areata (AA) is one of the most common autoimmune diseases and targets the hair follicles,
with high impact on the quality of life and self-esteem of patients due to hair loss. Clinical management and outcomes
are challenged by current limited immunosuppressive and immunomodulating regimens.
Methods: We have developed a Stem Cell Educator therapy in which a patient’s blood is circulated through a
closed-loop system that separates mononuclear cells from the whole blood, allows the cells to briefly interact
with adherent human cord blood-derived multipotent stem cells (CB-SC), and returns the “educated” autologous
cells to the patient’s circulation. In an open-label, phase 1/phase 2 study, patients (N = 9) with severe AA received one
treatment with the Stem Cell Educator therapy. The median age was 20 years (median alopecic duration, 5 years).
Results: Clinical data demonstrated that patients with severe AA achieved improved hair regrowth and quality of life
after receiving Stem Cell Educator therapy. Flow cytometry revealed the up-regulation of Th2 cytokines and restoration
of balancing Th1/Th2/Th3 cytokine production in the peripheral blood of AA subjects. Immunohistochemistry
indicated the formation of a “ring of transforming growth factor beta 1 (TGF-β1)” around the hair follicles, leading
to the restoration of immune privilege of hair follicles and the protection of newly generated hair follicles against
autoimmune destruction. Mechanistic studies revealed that co-culture with CB-SC may up-regulate the expression
of coinhibitory molecules B and T lymphocyte attenuator (BTLA) and programmed death-1 receptor (PD-1) on
CD8β+NKG2D+ effector T cells and suppress their proliferation via herpesvirus entry mediator (HVEM) ligands and
programmed death-1 ligand (PD-L1) on CB-SCs.
Conclusions: Current clinical data demonstrated the safety and efficacy of the Stem Cell Educator therapy for the
treatment of AA. This innovative approach produced lasting improvement in hair regrowth in subjects with
moderate or severe AA.
Trial registration: ClinicalTrials.gov, NCT01673789, 21 August 2012
Keywords: Alopecia areata, Autoimmune, Stem Cell Educator, Immune modulation, Hair regrowthBackground
Alopecia areata (AA) is one of the most common T cell-
mediated autoimmune skin diseases, leading to chronic
and relapsing hair loss. AA affects both children and
adults of all ages and on hairs of all colors, with a preva-
lence rate at 2% of the overall population without gender
predilection [1]. Clinical evidence supports a high* Correspondence: yzhao@hackensackUMC.org
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unless otherwise stated.prevalence of comorbid autoimmune conditions among
individuals with AA, such as thyroid disease, type 1 dia-
betes mellitus, inflammatory bowel disease, and systemic
lupus erythematosus [1,2]. The quality of life in AA pa-
tients has been significantly affected by the disappointing
outcomes, side effects, and relapses with current con-
ventional therapies, including topical and systematic ap-
plications of immunosuppressive regimens (such as
corticosteroids and cyclosporine) or immune modulators
(e.g., dithranol and diphenylcyclopropenone (DPCP))
[1,3]. To overcome these challenges, an innovative and
translational technology is necessary to advance theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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should address multiple or all of the underlying causes of
autoimmunity in AA. However, similar to all other auto-
immune diseases, possible triggers for autoimmunity in AA
include genetic, epigenetic, physical, emotional, social, and
environmental factors. These complicated factors may act
independently or jointly to break down the “immune privil-
ege” of hair follicles through different molecular and cellular
mechanisms, resulting in the autoimmune destruction of
hair follicles by multiple immune cells, such as CD4+ and/or
CD8+ T cells and natural killer (NK) cells [1,4-7]. Thus, a
comprehensive approach is needed to fundamentally restore
the immune privilege of hair follicles and address these mul-
tiple immune dysfunctions resulting from a variety of etio-
logical causes.
Hair follicles are normally immune privileged sites, similar
to other organ tissue systems, such as the brain, eye, and
testis, and they contribute to the regulation of homeostasis
through the neuroendocrine-immune network [8,9]. Under
physiological conditions, the maintenance of the immune
privilege status may include the following potential mecha-
nisms: a low expression or absence of major histocompati-
bility complex (MHC) class I antigens and MHC class I
chain-related A (MICA) molecules; a presence of function-
ally impaired Langerhans cells; and local expression of po-
tent immunosuppressants (for example, transforming
growth factor beta 1 (TGF-β1) and α-melanocyte stimulating
hormone (MSH)) [5-7,10]. It is well recognized that collapse
of hair follicle immune privilege leads to the onset of AA
[7,11-14]. Due to the complexity of AA-related autoimmune
responses and the similarity with other autoimmune dis-
eases, clinical therapies and trials that only target one or a
few components of the autoimmune responses are likely to
fail, as has been observed in recent clinical trials for type 1
diabetes [15-17]. Successful immune therapies will likely re-
store the immune balance and peripheral tolerance by a
comprehensive modulation within the entire human im-
mune system.
We have previously characterized a novel type of stem cell
from human umbilical cord blood, designated a cord blood-
derived multipotent stem cell (CB-SC) [18,19]. CB-SCs are
phenotypically and functionally different from other types of
stem cells [20], including hematopoietic stem cells (HSCs),
mesenchymal stem cells (MSCs), endothelial progenitor cells
(EPCs), and monocyte-derived stem cells [21,22]. Preclinical
work demonstrated the immune modulation capability of
CB-SCs in autoimmune-caused diabetic non-obese (NOD)
mice [23] as well as with autoreactive human T cells from
type 1 diabetic patients [19]. Recently, we reported on the
development of the Stem Cell Educator therapy utilizing cul-
tured CB-SCs in clinical trials for both type 1 and type 2 dia-
betes [20,24,25]. Clinical data demonstrated that a single
treatment with the Stem Cell Educator provided lasting re-
versal of autoimmunity and a rebalance of immuneresponses that allowed regeneration of islet β cells and im-
provement of metabolic control in subjects with long-
standing type 1 diabetes [20,24]. Additionally, a phase 1/2
clinical study demonstrated that Stem Cell Educator therapy
can control immune dysfunction and restore the immune
balance through the modulation of monocytes/macrophages,
leading to a long-lasting improvement of insulin sensitivity
and metabolic control in long-standing type 2 diabetic pa-
tients [25]. The combined preclinical and early clinical data
[19,20,23-26] raise the intriguing possibility that the Stem
Cell Educator therapy may also be useful in overcoming the
autoimmunity involved in AA. Here, we explore the thera-
peutic potential of Stem Cell Educator therapy in AA
subjects.
Methods
Cell proliferation and ex vivo co-cultures
Human buffy coat blood units were purchased from
the Blood Center of New Jersey (East Orange, NJ, USA).
Human peripheral blood-derived mononuclear cells
(PBMCs) were harvested as previously described [24,25].
The PBMCs were stimulated for 5 days with Dynabeads
coupled with anti-CD3, anti-CD28, and anti-CD137 anti-
bodies (Life Technologies, Grand Island, NY, USA) in the
presence of 50 U/ml recombinant human IL-2 (rIL-2) and
5 ng/ml recombinant human IL-7 (rIL-7) (R&D Systems,
Minneapolis, MN), and incubated at 37°C, in 8% CO2.
The proliferation of lymphocytes was stained and analyzed
with CellTrace™ CFSE Cell Proliferation kit (Life Tech-
nologies) following the manufacturer’s instructions. The
Dynabeads were removed for flow cytometry by using
DynaMag-15 (Life Technologies) according to the manu-
facturer’s instructions.
To perform ex vivo studies, human cord blood units
were provided by the CORD:USE Cord Blood Bank
(Orlando, FL, USA). All cord blood samples were
screened for alanine aminotransferase (ALT) and pa-
thogenic antigen antibodies (including anti-HCV, anti-
HBsAg, anti-HIV, anti-Syphilis, anti-Chlamydia, and
anti-Gonorrhea Abs), and only pathogen-free cord blood
units were used for isolating CB-SCs. Human cord
blood-derived stem cells (CB-SCs) were generated as
previously described [24,25] with the following modifica-
tions. Cord blood mononuclear cells were plated in
serum-free culture medium (Lonza, Walkersville, MD,
USA) and incubated at 37°C, in 8% CO2. After 2 to 3
weeks, CB-SCs growing at 80-90% confluence were pre-
pared for co-culture with allogeneic lymphocytes.
Flow cytometry
Flow cytometric analyses were performed as previously de-
scribed [23]. Cells were incubated with mouse anti-human
monoclonal antibodies (mAb; Beckman Coulter, Brea, CA,
USA), including APC-Alexa Fluor 750-conjugated anti-
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CD8α, anti-CD14, and anti-CD19, phycoerythrin (PE)-
conjugated anti-CD8β and anti-CD123, APC-conjugated
anti-CD11c, phycoerythrin-Cy7 (PE-Cy7)-conjugated anti-
BTLA, R Phycoerythrin-Cyanine 5.5 (PC5.5)-conjugated
anti-PD-1, and FITC-conjugated anti-HLA-DR. FITC-
conjugated mouse anti-human CD45 mAb was purchased
from BD Biosciences (San Jose, CA, USA). PE-conjugated
mouse anti-human CD270 (HVEM) mAb was purchased
from BioLegend (San Diego, CA, USA). Alexa Fluor 647-
conjugated rat anti-human Oct 3/4 mAb was purchased
from eBioscience (San Diego, CA, USA). Cells were stained
for 30 min at room temperature and then washed with
PBS prior to flow analysis. Isotype-matched mouse anti-
human IgG antibodies (Beckman Coulter) served as a
negative control for all fluorescein-conjugated IgG mAb.
For intracellular staining, cells were fixed and perme-
abilized using a PerFix-nc kit (Beckman Coulter). After
staining, cells were collected and analyzed using a Gallios
Flow Cytometer (Beckman Coulter), equipped with 3 lasers
(488 nm blue, 638 red, and 405 violet lasers) for the con-
current reading of up to 10 colors. The final data were ana-
lyzed using the Kaluza flow cytometry analysis software




Age Gender Marriage Duration
(year)
Diagnosis
1 21 M No 3 Patchy alopecia
Areata
2 26 F Yes 15 Patchy alopecia
Areata
3 12 F No 6 Patchy alopecia
Areata
4 20 F No 0.8 Alopecia totalis
5 18 F No 0.2 Alopecia totalis
6 24 M No 2 Alopecia universalis
7 17 M No 16 Alopecia universalis
8 17 M No 3 Alopecia universalis
9 26 F Yes 0.2 Alopecia universalis
Mean (SD) 20 (5) 5 (6)Patients
The AA subjects were consecutive patients receiving
care through the Department of Dermatology at the
First Hospital of Hebei Medical University (Shijiazhuang,
Hebei, China) who were enrolled in a phase 1/phase 2,
open-label clinical trial conducted from 29 August 2012
through 31 July 2014. With oversight from a planning
committee, the principal investigator designed the trial
and received ethical approval for the clinical treatment
protocol and consent from the First Hospital of Hebei
Medical University (Shijiazhuang, Hebei, China). Helsinki
protocols were followed. Participants and their parents
provided written informed consent to participate in this
study, and for the publication of images and details rela-
ted to the individual participants. Thirty subjects were
approached for the study. The trial was conducted with
nine subjects with established AA (mean alopecic duration
of 5 years) (Table 1). Patients were qualified for enroll-
ment if they met the Alopecia Areata Investigational As-
sessment Guidelines of the National Alopecia Areata
Foundation (NAAF). All subjects receiving Stem Cell Edu-
cator therapy had been treated with current standard ther-
apy, but the treatment failed. With at least a 3-month
washout period, subjects received one treatment with the
Stem Cell Educator therapy. Key exclusion criteria in-
cluded: clinical fever; clinically significant liver, kidney, or
heart disease; pregnancy; immunosuppressive medication;
viral and bacterial diseases; or diseases associated withimmunodeficiency; or any other clinically significant,
coexisting conditions.
Stem Cell Educator therapy and follow-up
Nine participants received a single treatment with the
Stem Cell Educator (Tianhe Stem Cell Biotechnologies®,
Jinan, China) and follow-up studies, as described in fol-
lowing diagram (Figure 1).
The preparation of CB-SC cultures and Stem Cell Educa-
tors was performed as previously described [24]. Briefly,
human cord blood units derived from healthy allogeneic
donors were obtained from Maternal and Child Health
Hospital (Jinan, Shandong, China). All cord blood sam-
ples were screened for alanine aminotransferase (ALT)
and pathogenic antigen antibodies (including anti-HCV,
anti-HBsAg, anti-HIV, and anti-Syphilis Abs), and only
pathogen-free cord blood units were used for isolating CB-
SCs. Human CB-SCs were generated as previously de-
scribed with the following modifications [18,23]. Cord
blood mononuclear cells were plated in serum-free culture
medium (Lonza, Walkersville, MD) and incubated at 37°C,
in 8% CO2. After 2 to 3 weeks, CB-SCs growing at 90%
confluence were prepared for clinical trial. The endotoxin
level was < 0.05 EU/ml. One Educator device was gener-
ated from one cord blood unit, and used for one subject.
For Stem Cell Educator therapy, a 16-gauge IV needle
was placed in the left (or right) median cubital vein, and
the patient’s blood was passed through a Blood Cell Sep-
arator MCS+ (Haemonetics®, Braintree, MA, USA) for 6
to 7 hours to isolate mononuclear cells in accordance
with the manufacturer’s recommended protocol. The
collected mononuclear cells were transferred into the
device for exposure to allogeneic CB-SCs, and other
blood components were automatically returned to the
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Figure 1 Diagram of Stem Cell Educator therapy for the treatment and follow-up studies.
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through the stacked discs of material with adherent CB-
SCs. After 2 to 3 hours in the device, CB-SC-treated
mononuclear cells were returned to the patient’s circula-
tion via a dorsal vein in the hand with physiological sa-
line (2 to 3 ml/min). Approximately 10,000 ml of blood
was processed during the procedure resulting in ap-
proximately two repeated educations for the lymphocyte
fraction. The whole process took 8 to 9 hours. During
the apheresis, some of the patients received oral calcium
gluconate solution (10%, 10 ml) to ease the tingling of
the lips or toes, due to the hypocalcemia caused by the
citrate anticoagulant. They did not receive any other
medications (such as antibiotics) during the course of
treatment. Patients were hospitalized for one day to
monitor temperature and conduct blood count tests for
adverse reactions following treatment. Follow-up visits
were scheduled 4, 12, 24, 40, 56, 84, and 112 weeks after
treatment for clinical assessments and laboratory tests.
Skin biopsies of scalps were performed before the treat-
ment and at 12 weeks post-treatment. The time points
for follow-up studies were similar for all subjects. Previ-
ous work demonstrated that participants receiving sham
therapy failed to show changes in immune modulation
[24]. Thus, the main outcome measures in the current
trial were changes in hair growth and immune markers
between baseline and follow-up.
Study end points
The primary study end points were feasibility and safety
of the Stem Cell Educator therapy through 24 weeks
post-treatment and preliminary evaluation of the efficacy
of the therapy for improving hair growth in AA subjects.
The secondary study end point was preliminary evidence
for efficacy of the therapy in modulating autoimmunity
by flow cytometry [24,25]. Baseline blood samples and
scalp tissues by biopsy were collected prior to Stem Cell
Educator therapy.
Immunohistochemistry and histology
Biopsied scalp tissues were fixed in 10% formaldehyde,
embedded in paraffin, and processed for hematoxylinand eosin (H&E) staining. To determine phenotypes of
infiltrated leukocytes and released cytokines, cryosec-
tions of frozen tissues were used. Cryosections (5 μm
thick) of frozen tissues from AA subjects before and
post-treatment with Stem Cell Educator therapy were
prepared using a Leica CM1850 cryostat [23]. Cryosec-
tions were immunostained with different mAbs includ-
ing FITC-conjugated anti-CD1c, anti-CD11b, anti-CD14,
anti-CD83, anti-DEC205 (eBioscience), anti-TGF-β1
(BioLegend), PE-conjugated anti-TGF-β1 (BioLegend),
and Alexa Fluor 488-conjugated anti-human Foxp3
(eBioscience), followed by imaging with an Olympus
IX71 inverted microscope. The fluorescence intensity
was measured by using the ImageJ 1.46 software.
Statistical analysis
An intention-to-treat approach was used, with nine pa-
tients undergoing Stem Cell Educator therapy. All pa-
tients were included in safety analyses. The primary
efficacy end points were hair regrowth and the change
in immune markers between baseline and follow-up.
Statistical analyses of data were performed using the
two-tailed Student’s t-test to determine statistical signifi-
cance. Values were given as mean ± SD (standard
deviation).
Results
Suppressed proliferation of antigen-specific T cells by
co-culture with CB-SCs
The expansion of antigen-specific autoreactive T cells is
the critical step leading to the destruction of tissues in
autoimmune diseases. Recently, mouse and human data
have demonstrated that CD8+NKG2D+ effector T cells
function as a key mediator in the pathogenesis of AA
[27]. To explore the therapeutic potential of CB-SC in
AA, CD8+NKG2D+ effector T cells from human periph-
eral blood mononuclear cells (PBMC) were activated
and expanded with Dynabeads coupled with anti-CD3,
anti-CD28, and anti-CD137 mAb in the presence of IL-2
and IL-7. After ex vivo expansion with this mAb com-
bination for 5 days, there were large numbers of cell clus-
ters with different sizes floating in the supernatant
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eration. However, this phenomenon was not evident in
the presence of CB-SCs (Figure 2A, right panel). Flow cy-
tometry revealed that 52% of lymphocytes proliferated in
response to costimulation with this combination of mAb
molecules and growth factors (Figure 2B, middle panel).
By contrast, there were only 13% of lymphocytes prolifer-
ating after co-culture with CB-SCs (Figure 2B, right
panel). Triple color staining demonstrated that 25% of
CD8+NKG2D+ T cells were proliferated upon costimula-
tion in the absence of CB-SCs. Notably, the percentage of
proliferating CD8+NKG2D+ T cells was reduced to 5% fol-
lowing co-culture with CB-SCs. Further multi-color flow
cytometry indicated that the percentage of CD8+NKG2D+
T cells was decreased from 25.6% ± 0.43% to 13.87% ±
3.43% in the presence of CB-SCs (Figure 2C, left panels)
P = 0.04). Additionally, we examined the expression ofB
A
Figure 2 Ex vivo studies of the immune modulation of CB-SCs on T cells. (
human peripheral blood-derived lymphocytes that were activated with Dyn
50 U/ml rIL-2, and 5 ng/ml rIL-7 for 5 days, in absence (left panel) and pres
panel) served as control. Original magnification, × 100. (B) Cell proliferation
lymphocytes (left panel) served as control. (C) Multi-color flow cytometry o
analyzed for the expression of coinhibitory molecules BTLA and PD-1. Iso
fluorescence intensity (MFI) was presented for CD8+NKG2D+BTLA+PD-1+ T ce
representative of three independent experiments with similar results.coinhibitory molecules on CD8+NKG2D+ T cells, such
as BTLA (B and T lymphocyte attenuator) and PD-1
(programmed death-1 receptor). Results confirmed that
co-culture with CB-SCs increased the percentage of
CD8+NKG2D+BTLA+PD-1+ T cells from 69% to 91%.
Their mean fluorescence intensity (MFI) also increased
after co-culture with CB-SCs (Figure 2C, right panels).
These data demonstrated that CB-SCs could markedly
suppress the proliferation of CD8+NKG2D+ T cells and
up-regulate the expression of coinhibitory molecules on
those cells. This finding supports the clinical-translational
potential of CB-SCs in AA subjects.
Expression of herpesvirus entry mediator (HVEM, CD270)
on CB-SCs
Human CB-SCs mediate immune modulation through
the release of soluble factors (for example, nitric oxideC
A) Phase contrast microscopy shows the formation of cell clusters in
abeads coupled with anti-CD3, anti-CD28, and anti-CD137 antibodies,
ence (right panel) of CB-SCs. Co-culture with lymphocytes (top right
was analyzed with CellTrace™ CFSE Cell Proliferation Kit. Untreated
n CD8+NKG2D+ T cells. The gated CD8+NKG2D+ T cells were further
type-matched IgG Abs served as control for flow cytometry. Mean
lls. Flow cytometry dot plots and the percentage of each population were
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such as PD-L1 (programmed death-1 ligand) [19,20,28].
To investigate additional potential molecular mecha-
nisms underlying the immune modulation, we also
found that CB-SCs strongly displayed the surface mol-
ecule HVEM (Figure 3A), the ligand of BTLA. Triple
color staining confirmed the co-expression of HVEM on
CB-SCs positive with molecular markers of leukocyte
common antigen CD45+ and embryonic transcription
factor Oct3/4+ (Figure 3B).To further substantiate that
HVEM may be a mechanism of immune modulation by
CB-SCs, flow cytometry also demonstrated the expres-
sion of BTLA and PD-1 on most immune cells, includ-
ing CD4+ and CD8β+ T cells, CD19+ B cells, CD14+
monocytes, CD11c+ myeloid dendritic cells (mDCs),
CD123+ plasmacytoid dendritic cells (pDCs), and CD66b+
granulocytes (Figure 3C). There were about 40-80%
BTLA+PD-1+ cells in each subpopulation of immune
cells (Figure 3D). These data suggest that CB-SCs may
display a broad spectrum of modulatory capacity on
immune cells via HVEM/BTLA and PD-L1/PD-1 sig-
naling pathways.A B
C
Figure 3 Flow cytometry analysis. (A) Expression of HVEM on CB-SCs. Isoty
gated CD45+Oct3/4+ CB-SCs. (C) Expression of BTLA and PD-1 on periphera
in each subpopulation. Each population was gated using the specific surfacHair regrowth in alopecia areata subjects
Nine AA subjects received one treatment with Stem Cell
Educator therapy and completed the study. All patients
tolerated the procedure well, without any significant ad-
verse events during the course of treatment. Their base-
line clinical characteristics are described in Table 1. No
participants experienced any significant adverse events
during the course of treatment and the 2-year follow-up
period. At 4 weeks post-treatment with Stem Cell Edu-
cator therapy, there was hair regrowth in subjects with
patchy AA and alopecia totalis (Figure 4). There were
short vellus hairs on the scalp of patients with AA uni-
versalis (3/4) at the 12-week follow-up. Two participants
(one having alopecia totalis and another having multiple
patches of AA) achieved complete hair regrowth at 12
weeks and 16 weeks, post-treatment, respectively, and
remained completely recovered with no relapse after 2
years (Figure 4). Patients (3/4) with alopecia universalis
exhibited regrowth of eyebrows and eyelashes at the 12-
week follow-up. Notably, the regrowth of eyebrows and
a mustache occurred in a 17-year-old boy affected by severe
alopecia universalis since he was 1 year old. Additionally,D
pe-matched IgG served as control. (B) Expression of HVEM on the
l blood-derived immune cells. (D) The percentage of BTLA+ PD-1+ cells








Figure 4 Regrowth of hair following Stem Cell Educator therapy.
A subject with severe AA (patient 4 in Table 1) achieved complete
hair regrowth at 12 weeks follow-up after receiving Stem Cell
Educator therapy and maintained regrowth through the last
follow-up (2 years).
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indicated by the reduction of the number and the cavity
of nail pitting at 4 weeks after receiving Stem Cell Edu-
cator therapy. All of these improvements were main-
tained throughout the final follow-up at 2 years. Of
nine AA subjects, only one participant with alopecia uni-
versalis failed to show a response to the Stem Cell Educa-
tor therapy, possibly due to a previous long-term therapy
with oral prednisone. Overall, the proof-of-concept data
demonstrated the therapeutic potential of Stem Cell Edu-
cator therapy for the treatment of AA subjects.
Systematic immune modulation after receiving Stem Cell
Educator therapy
To explore the immune modulation of Stem Cell Educa-
tor therapy in AA subjects, we examined changes in thepercentage of regulatory T cells (Treg) in their periph-
eral blood by using the specific intracellular marker,
FoxP3. Flow cytometry revealed that the percentage of
FoxP3+ Treg at 4 weeks was unchanged from the base-
line (1.69% ± 1.02 versus 1.38% ± 0.85, P = 0.49). This re-
sult suggested that the immune modulation via Stem
Cell Educator therapy in AA subjects may act through a
different mechanism than induction of Treg. TGF-β1,
one of the best-characterized cytokines contributing to
the induction of peripheral immune tolerance [29], also
plays a crucial role in modulating the normal cycling of
hair follicles [30]. Flow cytometry demonstrated a
marked increase in TGF-β1 expression by blood mono-
nuclear cells 4 weeks after receiving Stem Cell Educator
therapy (P = 0.015, Figure 5A). Additionally, participants
exhibited significant up-regulation of Th2 cytokines IL-4
and IL-5 expression at the 4-week follow-up (P = 0.012
and P = 0.022, respectively, Figure 5A). Expression of IL-
13 was also significantly increased in 6/9 participants
(3.69 ± 3.27 versus 15.55 ± 7.48, P = 0.005). No changes
were observed in the level of Th1 cytokine IL-12 (P = 0.24,
Figure 5A). Thus, these data suggested that the up-
regulation of Th2 cell responses may suppress the Th1
cell-mediated autoimmune response in AA subjects
[1,4,31] via associated cytokines [32]. The Stem Cell Edu-
cator therapy may shift the balance towards Th2-mediated
immune responses, leading to the clinical efficacy in AA
subjects.
The costimulatory molecule, CD28, functions as a key
signal leading to Th2 cell differentiation and activation
[33-36]. To determine changes in expression of costimu-
latory molecules, we examined lymphocytes for their
levels of CD28 and inducible costimulator (ICOS). Flow
cytometry demonstrated that the expression of CD28
was markedly increased in 8/9 participants 4 weeks after
Stem Cell Educator therapy (P = 0.013, Figure 5B), but
levels of ICOS were unchanged in all participants (P = 0.84,
Figure 5B). Therefore, the up-regulation of CD28 expres-
sion, together with the increase of IL-4 production in
AA subjects, can provide critical signals that shift the dif-
ferentiation of human CD4+ T cells into Th2 cells [36]
and attenuate Th1 cell responses.
Formation of a “ring of TGF-β1” leading to local immune
modulation and restoration of immune privilege of hair
follicles after Stem Cell Educator therapy
To clarify the molecular and cellular mechanism under-
lying the regrowth of hairs and the immune modulation,
we performed immunohistochemistry on fresh tissues via
the biopsy of alopecic lesions from subjects after receiving
Stem Cell Educator therapy. The histology of the alopecic
lesions demonstrated a dense, perifollicular lymphocytic
infiltration around anagen hair follicles. Twelve weeks




















































Figure 5 Immune modulation of Stem Cell Educator therapy. Patient lymphocytes were isolated from peripheral blood by Ficoll-Hypaque technique
(γ = 1.077) for flow cytometric analyses in AA patients at baseline and 4 weeks after Stem Cell Educator therapy. Isotype-matched IgG served as control.
Histologic examination of alopecic skin (C and D). (A) Flow analysis of intracellular cytokines demonstrating differential effects on key interleukins at 4
weeks post-treatment. (B) Flow analysis of costimulating molecules demonstrating an increase of CD28 expression at 4 weeks post-treatment. Data
are representative of preparations from all AA participants (n = 9) who received Stem Cell Educator therapy. (C) Fresh skin tissues were collected from
the scalps via biopsy for immunohistochemistry testing in participants with alopecia totalis before treatment and 12 weeks after receiving Stem Cell
Educator therapy. TGF-β1 staining surrounds a hair follicle of AA participants after receiving Stem Cell Educator therapy, with vertical section of hair
follicle (top panels) and horizontal section of hair follicle. Isotype-matched mouse IgG1 served as a negative control for TGF-β1 immunostaining in a serial
hair follicle section. Representative images were obtained from five experiments. Scale bar, 25 μm. (D) H&E staining of scalp tissues. Scale bar, 25 μm.
Li et al. BMC Medicine  (2015) 13:87 Page 8 of 11examination revealed the restoration of hair follicle archi-
tecture and the disappearance of the substantial perifolli-
cular infiltration of lymphocytes. Additionally, horizontal
sections confirmed an increase in the density of total hair
follicles in these participants with alopecia totalis.
TGF-β1 is a pleiotropic growth factor that plays a key
role not only in the induction of local immune tolerance
[29], but also in the regulation of cycling of hair follicles
via the inhibition of keratinocyte proliferation and the
induction of apoptosis [30,37,38]. Previous works demon-
strated that TGF-β1 contributed to the therapeutic effi-
cacy of Stem Cell Educator therapy in both autoimmune-
caused diabetic NOD mice [23] and diabetic patients
[24,25]. Notably, in addition to the up-regulation of TGF-
β1 expression in the peripheral blood mononuclear cells
(Figure 5A), immunohistochemistry demonstrated that
the level of TGF-β1 expression post-treatment (21.78 ±
0.27) was much higher than that of baseline before treat-
ment (5.14 ± 0.01, P = 3.14337E-14), specifically at the
proximal anagen hair follicle (Figure 5C, middle panel).
The expression of TGF-β1 formed a cycle around the hair
follicles (Figure 5C, bottom panel), similar to the “ring of
TGF-β1” that we observed in a previous study [23]. Itsuggested that this unique feature of TGF-β1 distribution
may contribute to reconstitution of the immune privilege
of hair follicles and protect the regenerated hair follicles
against further destruction by autoimmune cells. HE stain-
ing further demonstrated the reduction of immune cell in-
filtration and restoration of normal architecture of the
hair follicles (Figure 5D).
To elucidate the major origin of the TGF-β1 production
involved in the formation of the “ring of TGF-β1,” we per-
formed double immunostaining in biopsied tissues by
using the markers of monocyte/macrophage (CD14 and
CD11b), Langerhans/dendritic cells (CD83 and DEC205),
myeloid dendritic cells (CD1c), and Treg FoxP3, respect-
ively. There were a few CD14+ monocytes/CD11b+ mac-
rophages, Langerhans/dendritic cells (positive with CD83,
DEC 205, or CD1c), and FoxP3+ Treg cells distributed in
the dermal tissues. Double immunostaining showed weak
staining for TGF-β1 in these immune cells, indicating that
these immune cells were not the major source of TGF-β1.
Notably, we found that there was a strong expression of
TGF-β1 in the proximal root sheath of hair follicles of
participants after receiving Stem Cell Educator therapy
(Figure 5C, bottom panels) relative to the baseline level
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cytes were recovered after receiving Stem Cell Educator
therapy and became the major TGF-β1-producing cells
leading to the restoration of immune privilege and the in-
duction of immune tolerance in hair follicles. The molecu-
lar mechanisms underlying the up-regulation of TGF-β1
in keratinocytes need to be clarified in future studies.
Discussion
AA is a devastating autoimmune disease that affects pa-
tients’ daily lives. Immune dysfunction of AA subjects is
complicated, not only localizing in hair follicles, but also
having effects outside of hair follicles with the develop-
ment of other autoimmune diseases. Overcoming the
autoimmunity represents one of the key hurdles in the
treatment of AA. Systematic applications of immuno-
suppressive regimens usually yield significant side ef-
fects. Localized therapies have been widely utilized in
clinic, including intralesional injections of glucocorti-
coids and the use of topical sensitizers through the in-
duction of contact allergy (for example, dithranol and
diphenylcyclopropenone), as well as topical corticosteroids
and minoxidil [1,3,39]. To date, although a multitude of
therapeutic options exist, neither local treatments nor sys-
tematic approaches can provide a cure for AA subjects
[1,39]. Current clinical proof-of-concept data reveal the
safety and efficacy of the Stem Cell Educator therapy ap-
proach in the treatment of AA subjects, as demonstrated
by clinical outcomes in hair regrowth. This finding opens
up a new avenue for AA clinical treatment by using the
comprehensive immune modulation induced by Stem Cell
Educator therapy. Because this disorder affects children of
all hair colors [1], it is important to highlight that pediatric
apheresis presents unique challenges due to children’s low
body weight (<40 kg) and height (<140 cm) and the diffi-
culties in vascular access and clinical monitoring. To over-
come these technical hurdles and improve the safety in
pediatric apheresis, alternative approaches should be con-
sidered for the treatment of pediatric AA subjects such as
the application of a different apheresis machine with low
extracorporeal blood volume, blood priming, and femoral
vein catheterization.
AA is characterized as a T cell-mediated autoimmune
disease, and CD8+ T cells seem to dominate the re-
sponse. They may recognize the MHC class I-restricted
melanogenesis-associated autoantigens and/or anagen-
associated hair follicle autoantigens and thereby mediate
the destruction of hair follicles [1,14]. More recently,
CD8β+NKG2D+ T cells have been characterized as a
major player leading to the autoimmune destruction of
hair follicles [27]. Therefore, it is essential to attenuate
these effector CD8+ T cells through the induction of per-
ipheral immune tolerance to these self-antigens. Notably,
we found that co-culture with CB-SCs could suppress theproliferation of activated CD8β+NKG2D+ T cells and
reduce their percentage. Up-regulation of the expres-
sion of coinhibitory molecules BTLA and PD-1 on
CD8β+NKG2D+ T cells may further attenuate their
cytotoxic effects. The current study confirmed the ex-
pression of BTLA ligand HVEM on CB-SCs. Previous
work demonstrated that the strong expression of pro-
grammed death-1 ligand (PD-L1) on CB-SCs contrib-
uted to the immune modulation of CD8 T cells [28].
Thus, CB-SCs may directly modulate CD8β+NKG2D+
T cells through the PD-1/PD-L1 and BTLA/HVEM
pathways.
Additionally, CB-SCs strongly express the autoimmune
regulator (Aire) [24] transcription factor. Aire proteins
are usually found in thymic medullary epithelial cells,
which play a central role in T cell development and the
induction of immune tolerance by mediating ectopic ex-
pression of peripheral self-antigens and mediating the
deletion of autoreactive T cells [40,41]. Knockdown of
Aire protein expression resulted in a reduction of PD-L1
expression on CB-SCs. Thus, we hypothesize that, in a
way, the Stem Cell Educator therapy may function as
“an artificial thymus” that circulates a patient’s blood
through a blood cell separator [20], briefly allows inter-
actions between T cells and other immune cells with
CB-SCs in vitro, induces immune tolerance through the
actions of Aire [24], expression of PD-L1 and HVEM,
the release of soluble factors (nitric oxide and TGF-β1),
and cell-cell contacting mechanisms [20,28], returns the
educated autologous lymphocytes to the patient’s circu-
lation, and achieves immune balance and homeostasis in
these AA subjects. Of interest, apheresis only withdraws
approximately 10-15% of all lymphocytes, and since
many pathogenic immune cells likely remain in the hair
follicles and the connective tissue sheath which fail to
enter into the blood circulation during the apheresis
procedure, many autoimmune cells escape direct inter-
action with the CB-SCs. This would suggest that some
of the cells altered by direct encounter with CB-SC can
spread the tolerance systemically. Additionally, due to
the short life span of most lymphocytes, subjects with
severe AA may need additional treatments, perhaps at
3- to 6-month intervals, to improve the efficacy and pos-
sibly prevent the relapse of disease. To improve the clin-
ical efficacy of Stem Cell Educator therapy, the sooner
treatment with this therapy begins after diagnosis, the
higher the chance of rescuing hair follicles and finding a
cure for AA.
Animal and clinical studies demonstrated that both
CD4+ Th1 cells and CD8+ T cells are required for the
pathogenesis of AA [1,4,42]. Up-regulation of Th1 cyto-
kines in AA subjects, not Th2 cytokines, exacerbates the
autoimmune destruction [31,43,44]. Kubo and colleagues
reported that there was a positive correlation between
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inversely proportional to the number of IL-4-producing
Th2 cells [45]. Therefore, the promotion of Th2 immune
responses has been proposed to be beneficial for the
treatment of AA patients [1,4]. The current study dem-
onstrated that Th2 response-associated cytokines such
as IL-4, IL-5, and IL-13 in these AA subjects were mark-
edly increased after receiving Stem Cell Educator ther-
apy. Additionally, CD28, one of the major costimulatory
molecules contributing to the differentiation of Th2 cells
[33-36], was up-regulated after Stem Cell Educator ther-
apy. Thus, the combination of CD28 + IL-4 can provide
key signals facilitating naïve or memory CD4+ T cells
and giving rise to Th2 cells via the activation of mitogen-
activated protein (MAP) kinase and extracellular signal-
regulated kinase (ERK) signaling pathways [36]. Conse-
quently, these Th2 cells and their cytokines may antagonize
Th1 cell functions and counterbalance their AA-related
autoimmune responses [32].
Collapse of immune privilege in hair follicles is the
major cause of pathogenesis in AA. Due to constitutively
low or absent expression of MHC class I antigen in the
proximal hair follicle epithelium, hair follicles may ini-
tially be attacked by NK cells through NK cell function-
activating receptors NKG2D and NKG2C [5,46]. Thus,
attenuating NK cells is also necessary to reestablish the
immune privilege and fundamentally advance the clinical
outcomes for the treatment of AA. Notably, current data
provide evidence for the up-regulation of TGF-β1 pro-
duction in peripheral blood mononuclear cells, as well
as the formation of a “ring of TGF-β1” in hair follicles of
AA subjects after receiving Stem Cell Educator therapy.
TGF-β1 can significantly suppress the proliferation and
activity of NK cells [47], in addition to its effects on
CD4+ and CD8+ T cells [29]. Thus, TGF-β1 may play a
key role in the restoration of immune privilege of hair
follicles and the induction of local immune tolerance.
It is also well known that TGF-β1 is a pleiotropic
growth factor that plays a key role in the production and
remodeling of the extracellular matrix [48]. Animal stud-
ies show that TGF-β1 acts as an essential factor contrib-
uting to the regulation of cycling and remodeling of hair
follicles via the inhibition of keratinocyte proliferation
and induction of apoptosis [30,37,38], as well as one of
the key niche factors that regulate melanocyte stem cell
immaturity and quiescence in the bulge area of hair folli-
cles [49]. Previous work demonstrated that the forma-
tion of a “ring of TGF-β1” around pancreatic islets may
protect the newly regenerated islet β cells against infil-
trating lymphocytes and macrophages [23], providing a
safe environment for promotion of regeneration of pan-
creatic islet β cells in long-standing type 1 diabetic
patients [20,24]. Thus, the formation of a “ring of TGF-
β1” may not only protect hair follicles through therestoration of immune privilege, but may also lead to the
activation of epithelial hair follicle stem cells and hair re-
growth. Additional molecular and cellular mechanisms
underlying the Stem Cell Educator therapy in humans
can be further explored by studying easily accessible and
abundant hair follicles. Thus, clinical success in AA by
the Stem Cell Educator therapy approach may open up
new avenues for the treatment of other autoimmune
diseases.
Conclusions
AA is one of the most common skin autoimmune dis-
eases, significantly affecting the life quality of patients.
The current phase 1/phase 2 study demonstrates the
safety and feasibility of Stem Cell Educator therapy in
the treatment of AA subjects. Findings from this trial
provide visible evidence that Stem Cell Educator therapy
can control the autoimmunity and lead to hair regrowth.
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